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Abstract
Objective
Beyond the joints, TNFi (tumour necrosis factor inhibitor) therapy may confer systemic ben-
efits in rheumatoid arthritis (RA). Several studies have investigated the role of TNFi on insu-
lin resistance/sensitivity (IR/IS). This question is of general interest given the emerging
evidence linking inflammation and insulin resistance. The main aim of this review was to
summarise the published data and to determine the effects of TNFi on IR/IS.
Methods
We searched the PubMed and ISI Web of Knowledge databases for studies which exam-
ined the effects of TNFi on IR/IS. The studies were assessed independently by two review-
ers according to a pre-specified protocol. The data on Homeostatic Model Assessment for
Insulin resistance (HOMA) and Quantitative Insulin Sensitivity Check Index (QUICKI) were
pooled and reported as standard difference in means (SDM) with 95% confidence interval
(CI) using a random-effects model.
Results
A total of eight studies with 260 subjects met the selection criteria. The duration of the stud-
ies was from 8 weeks to 12 months. There was statistically significant reduction in HOMA
index in six out of eight studies and four reported significant increment in QUICKI. The
pooled analysis revealed significant reduction in HOMA [SDM-0.148, 95%CI[-0.278 to
-0.017], p=0.026] and increment in QUICKI [SDM 0.312, 95%CI[0.019 to 0.606], p=0.037]
with TNFi.
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Conclusion
There is emerging evidence to support that TNFi therapy improves IS and reduces IR in RA.
Further, well conducted trials are needed to determine if such effects translate to lower inci-
dence of diabetes in RA or other autoimmune conditions on biologic therapy.
Introduction
There is an established link between systemic inflammation and insulin resistance (IR). Several
studies have highlighted an inverse relationship between disease activity scores in Rheumatoid
Arthritis (RA) and beta cell function [1]. Severe insulin resistance is present even in early
untreated RA patients [2]. Accumulating evidence supports a significant association between
IR and the culprit cytokines in RA such as tumour necrosis factor (TNF) α, interleukin 1 and
interleukin 6 [3–6]. The precise mechanism remains elusive but a complex adipokine-mediated
interaction among adipose tissue, IR and RA has been implicated [7]. In RA, adipocytes and
the surrounding macrophages produce a wide range of adipokines including resistin. Resistin
interferes with glucose homeostasis by opposing the actions of insulin leading to IR [8].
TNF inhibitors (TNFi) have revolutionised the therapeutic arena of RA in the recent
decades. Beyond the joints, TNFi therapy likely confers systemic benefits [9]. Several studies
have examined the effects of TNFi therapy on IR. These studies were conducted using commer-
cially available TNFis namely, infliximab, etanercept and adalimumab. Theoretically, TNF
blockade enhances insulin sensitivity (IS) by increasing the tyrosine kinase activity of the insu-
lin receptor and promotes insulin-glucose-mediated uptake in the skeletal muscle [10].
Improved insulin resistance, however, may not be solely due to the effects of TNFi. Effective
suppression of the inflammatory process could be partially explanatory. Anti-TNF therapy
may improve insulin resistance in RA patients by reversing defects in the phosphorylation/acti-
vation status of the insulin signaling pathway [11]. The vast majority of the studies in the litera-
ture assessed IR by the HOMA (Homeostasis Model Assessment of Insulin Resistance) and the
QUICKI (Quantitative Insulin Sensitivity Check Index). The HOMA was developed from
physiological studies into mathematical equations describing glucose regulation by estimating
insulin resistance and β-cell function from fasting glucose and insulin levels [12]. The QUICKI,
on the other hand, measures IS using the inverse of the sum of the logarithms of the fasting
insulin and fasting glucose [13]. A recent systematic review shows that HOMA-IR and
QUICKI have reasonable associations with clamp a ‘gold standard’ measure of peripheral insu-
lin sensitivity [14].
The main objective of this systematic review is to evaluate the published data to determine
the effects of TNFi on IR/IS. This is an interesting question since diabetes rates might be altered
by anti-inflammatory therapy, in particular biologics, but randomised trials are sparse. We
therefore sought to capture best available evidence on effects of biologics on the key pathways
leading to diabetes, namely insulin resistance.
Methods
Data Sources and Searches
We followed the MOOSE (Meta-analysis of observational studies in epidemiology) guidelines
for reporting systematic reviews and meta-analyses. Two authors (RS and ANB) independently
screened articles for inclusion in this systematic review by going through the abstracts retrieved
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from the search strategy. The PubMed, ScienceDirect and ISI Web of Knowledge databases
were searched for articles published from 1999 to 2014 designed as: clinical trials, randomized
controlled studies, observational (prospective and cross-sectional) studies that evaluated the
effects of TNFi on IR/IS in RA. Search terms included various combinations of the following:
“TNF antagonists”, “adalimumab (ADA)”, “etanercept (ETN)”, “infliximab (IFX)”,”certolizu-
mab”, “golimumab”, “insulin resistance (IR)”, “insulin sensitivity (IS)” and “rheumatoid arthri-
tis (RA)”. Articles identified during the initial screening process as potentially relevant were
brought forward for full-text review. Disagreements among the authors were resolved by con-
sensus. The bibliographies of relevant studies and narrative reviews were searched for further
relevant publications.
Study selection
The following studies were eligible for inclusion:
1. studies involving RA patients.
2. longitudinal studies which investigated the association between TNFi therapy and either the
HOMA index and/or the QUICKI.
3. studies published in English.
We excluded conference abstracts, case reports, cross-sectional studies and proceedings.
Search strategy is presented on Fig 1.
Fig 1. Flow chart of studies identification and selection.
doi:10.1371/journal.pone.0128889.g001
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Data extraction and Quality Assessment
We extracted the following data from the selected studies: year, study design, study population,
sample size, type of TNF antagonist, comparator drug, and the study duration. The following
outcome measures were used to evaluate the effect of TNF inhibition on IR/IS; the HOMA and
QUICKI indices. The values of these indices as well as the p values were collected. As for studies
which provided the median values, we estimated the means following the formula by Hozo
et al [15]. The quality of the controlled studies was assessed based on the “Instrument to mea-
sure the likelihood of bias”, proposed by Jadad et al [16].
Data Synthesis and Analysis
Data were pooled using a random effects model for a more conservative but precise estimate of
the effects of TNF antagonist on IR/IS. This model allows for heterogeneity across the studies
[17]. The data on the outcome of TNF antagonist therapy versus controls were expressed as
standard difference in means (SDM) with 95% confidence intervals (CIs). Comprehensive
Meta-analysis software version 2.0 was used to analyse the data and generate the Forest plots of
the pooled data. Egger’s test was used to evaluate publication bias for the meta-analysis of the
HOMA and QUICKI indices Fig 2).
Results
Based on the prespecified eligibility criteria, a total of eight studies were selected for this sys-
tematic review [11, 18–24]. All these studies are presented in Table 1. Four of the eight studies
[11, 19, 21, 24] employed control groups. The controls were patients on conventional
DMARDs i.e. methotrexate, leflunomide, sulfasalazine, healthy controls or on non-TNFi bio-
logic i.e. abatacept. All the controlled trials were neither randomised nor double blinded and
did not describe the withdrawals and drop-outs. Hence, the Jadad score was 0 for these studies
[11, 19, 21, 24]. The TNFis which were investigated in this series include etanercept (four stud-
ies with 34 subjects) [11, 18, 19, 24], infliximab (seven studies with 147 subjects) [11, 18–20,
22–24] and adalimumab (four studies with 29 subjects) [11, 18, 19, 21]. Despite certolizumab
Fig 2. Funnel plots (A) for HOMA from 8 selected studies and (B) for QUICKI from 4 selected studies evaluating effects of TNFi on IR/IS.
doi:10.1371/journal.pone.0128889.g002
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pergol and golimumab being included in our search, we were not able to identify a single study
evaluating insulin sensitivity/resistance with these pharmaceuticals. Across the studies, the
sample size ranged from seven to 61 subjects. The duration of the studies was from 8 weeks to
12 months. The study by Seriolo et al was not included in the statistical analysis as no standard
deviation (SD) values were provided in the paper.
Five out of eight of the studies [20, 21, 24–26]allowed low and stable doses of prednisolone
of less than 10 mg throughout the studies. In the study by Ferraz-Amaro et al [27], none of the
Table 1. Summary of the studies evaluating the Effects of TNFi Therapy on IR/IS in RA.
HOMA-IR QUICKI
Author, year and ref Number of
subjects
Concomitant medications
in the TNFi arm
Duration of
follow up
Pre TNFi Post TNFi p value Pre TNFi Post TNFi p value
Mean (SD) Mean (SD)
Stavropoulos-
Kalinglou et al. 2012
[18]
IFX n = 20 NA 6 months 2.6 (0.60) 2.4 (0.80) 0.088 0.33 (0.02) 0.36 (0.02) 0.092
ETN n = 11
ADA n = 1
Mean (95%CI) Mean (95%CI)
Stagakis et al. 2012
[11]
IFX n = 49 NA 12 weeks 7.00 (5.20–9.40) -5.68 (-8.86-
[-2.50])
0.001 0.29 (0.28–0.30) 0.07 (0.04–0.09) 0.001
ADA n = 11
ETN n = 1
Controls ABA
n = 7
Median (IQR)
Ferraz-Amaro et al.
2011 [19]
ADA n = 8 NA 12 months 1.60 (0.80) 1.60 (0.60) 0.24 —
IFX n = 6
ETN n = 2
Controls
Biologic Naive
n = 34
Healthy
subjects n = 70
Mean Mean
Seriolo et al. 2008
[24]
ETN n = 20 Stable doses of NSAID and MTX
(10 mg/wk)
24 weeks 1.44 1.73 0.01 0.36 0.37 0.01
IFX n = 18
Controls TNFi
Naïve n = 20
Mean (95%CI)
Rosenvinge et al.
2007 [21]
ADA n = 9 8 weeks 1.40 (0.30) 1.30 (0.30) 0.05 —
Controls
Healthy
Subjects n = 9
Mean (SD)
Oguz et al. 2007 [22] IFX n = 7 9.6 months
(mean)
2.40 (1.00) 1.10 (0.50) 0.05 —
Median (IQR)
Tam et al. 2007 [20] IFX n = 19 All subjects on the same dose of
NSAID and oral prednisolone
10 mg/day.
14 weeks 1.34 (0.63–2.13) 0.58 (0.43–
1.30)
0.05 —
Mean (SE) Mean (SE)
Kiortsis et al. 2005
[23]
IFX n = 28 Prednisolone (5 mg/day) and
CSA or MTX
6 months 3.01 (0.48) 1.89 (0.35) 0.01 0.30 (0.01) 0.35 (0.01) <0.010
ABA-Abatacept, ADA-Adalimumab, CI-Conﬁdence Interval, CSA-Cyclosporine, ETN-Etanercept, HOMA-Homeostatic Model Assessment for insulin
resistance, IFX-Inﬂiximab, IQR-interquartile range, IR-Insulin Resistance, IS-Insulin Sensitivity, MTX-Methotrexate, NSAID-Non Steroid Anti-Inﬂammatory
Drugs, QUICKI-Quantitative Insulin Sensitivity check Index, SD-Standard Deviation, SE–Standard Error, TNFi-Tumour Necrosis Factor α inhibitor.
doi:10.1371/journal.pone.0128889.t001
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subjects received steroids. Two of the remaining studies (Stavropoulos-Kalinglou et al and Sta-
gakis et al)[11, 18] did not provide any information on the use of steroids. Six out of 8 [11, 18,
21, 25, 26, 28] of the included studies excluded subjects with diabetes mellitus.
Effects of TNFIs on HOMA
All 8 studies assessed insulin resistance by HOMA index with a combined total of 210 subjects
[11, 18–24]. Out of the 8 studies, 6 showed significant decrease in HOMA index after TNFi
treatment [11, 18, 20, 22–24]. The mean duration of the studies was 24.05 weeks (~6 months).
A significant change in the HOMA index was detected as early as 8 weeks. Our pooled analysis
with 7 studies [11, 18–23] revealed a significant improvement in HOMA index with TNFi ther-
apy (SDM -0.191, 95%CI [-0.370 to -0.012], p = 0.037) (Fig 3). The inter-study heterogeneity
test was not statistically significant with a p value of 0.255 and I2 of 21.98%.
Effects of TNFIs on QUICKI
Only 4 studies [11, 18, 23, 24] used QUICKI to evaluate insulin sensitivity. QUICKI was calcu-
lable for a total of 159 subjects. Significant increase in QUICKI values was recorded in all 4 [11,
Fig 3. The Forest Plot for the effect of TNFi on HOMA index.
doi:10.1371/journal.pone.0128889.g003
Fig 4. The Forest Plot for the effect of TNFi on QUICKI.
doi:10.1371/journal.pone.0128889.g004
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18, 23, 24, 29] of the studies. The mean duration was 21 weeks (5.25 months). The study with
the shortest duration showing significant changes in QUICKI lasted for 12 weeks [11]. Our
pooled analysis with 3 studies [11, 18, 23] showed a significant increase in QUICKI with TNFi
(SDM 0.393, 95%CI [0.014 to 0.772], p = 0.042) Fig 4). The heterogeneity test yielded a value of
I2 = 65.19% which was statistically significant (p = 0.035).
Discussion
This systematic review and meta-analysis highlighted that there is evidence supporting the
beneficial effects of TNFi therapy on insulin sensitivity in RA. The pooled analysis of both the
outcome measures i.e. HOMA and QUICKI were consistent, though heterogeneity in QUICKI
was evident. The HOMA index which reflects insulin resistance, decreased significantly in all
except for 2 studies. Nevertheless, the combined results suggest an improvement in insulin sen-
sitivity with TNFi treatment. The relevance of these studies is that impaired glucose tolerance
is more prevalent among patients with RA compared to the healthy controls [30]. Studies have
consistently demonstrated that the degree of the impaired glucose metabolism was related to
the severity of the inflammatory activity [31, 32]. It is therefore predicted that biologics would
lessen such abnormalities in patients with RA. Our work also support the findings of a poten-
tially beneficial effect of TNFi on the risk of diabetes mellitus (lower by 51%) based on data
from an inception RA cohort [33].
The reduction in the HOMA, however, may not be exclusively seen only with TNFi therapy
in RA. Cross sectional studies by Perez et al and Cuchacovich et al [34, 35] found no difference
in the HOMA index between the TNFi arm and the methotrexate (MTX) treated arm. In a
recent study by Rajappa et al [36] systemic MTX therapy was associated with a significant
reduction in insulin levels and insulin resistance indices in patients with psoriasis vulgaris.
Whether the same holds true in RA remains unknown owing to the lack of well-designed ran-
domised controlled trials in this regard. It is noteworthy that Seriolo et al [24], who performed
a head-to-head comparison between TNFi and MTX therapy, demonstrated a significant
decrease in the HOMA index compared to baseline at 24 weeks in the TNFi arm (1.445 vs
1.733; p<0.01) but there were no changes observed in the controls on MTX therapy. This find-
ing however, should be interpreted cautiously given that the control arm was on a relatively
low dose of MTX i.e. 10 mg weekly.
Across the studies which investigated the changes in QUICKI with TNFi, there was broad
consistency. All 5 studies reported a significant increment in this parameter. The improvement
in insulin sensitivity with TNFi therapy observed in RA does not echo the findings in other dis-
ease conditions such as diabetes mellitus and inflammatory bowel disease [37–39]. Ofei et al.
[37] reported that the fasting glucose, fasting insulin and C-peptide levels were unaffected by
TNFi therapy in obese Type 2 diabetics. Along this line, Stavropoulos-Kalinglou et al. [18]
reported that improvement in HOMA and QUICKI were seen only in the normal weight IR
patients and not in the obese subjects.
Gentile et al [38], on the other hand found that infliximab did not interfere with insulin
secretion, insulin resistance and production of antibodies to glutamic acid decarboxylase and
islet cells in patients with Crohn's disease. It is tempting to speculate that TNFi therapy was
ineffective in enhancing insulin sensitivity in the above conditions due to impaired insulin sig-
nalling through other mechanisms independent of TNFα or systemic inflammation.
We do acknowledge the limitations of this systematic review. Studies included in this review
were mainly observational. Observational studies are prone to methodological bias and cannot
prove causality. Further the study designs were rather heterogenous making direct compari-
sons difficult. In addition, most of the studies did not perform adjustments for potential
TNF-Inhibitors and Insulin Sensitivity
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confounding factors in particular changes in body mass index, smoking, or by capturing cumu-
lative dose of TNFi, and/or changes in corticosteroids. The results of this systematic review
should be interpreted with great caution as the aforementioned confounders were not adjusted
for in the analyses. Therefore, the present findings should be seen as hypothesis generating and
data from randomised trials are needed to definitively prove a link between inflammation sup-
pression via biologics and changes in insulin resistance.
Conclusion
This systematic review provides further evidence that TNFi therapy likely enhances IS in
patients with RA. The work support the need for further trials in this area and to link such
changes to clinical end-points, in particular risk for diabetes in patients with RA and other
auto-immune conditions.
Supporting Information
S1 Appendix. Excluded articles.
(DOCX)
S2 Appendix. PRISMA checklist.
(DOC)
Author Contributions
Conceived and designed the experiments: AB RS. Performed the experiments: AB RS. Analyzed
the data: RS NS. Contributed reagents/materials/analysis tools: RS AB. Wrote the paper: AB RS
NS. Contributed to the conceptual framework of the paper: RS.
References
1. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis
& Rheumatism.2006; 54(9):2765–75.
2. Shahin D, Eltoraby E, Mesbah A, Houssen M. Insulin resistance in early untreated rheumatoid arthritis
patients. Clinical biochemistry.2010; 43(7–8):661–5. doi: 10.1016/j.clinbiochem.2010.01.012 PMID:
20144599
3. La Montagna G, Cacciapuoti F, Buono R, Manzella D, Mennillo GA, Arciello A, et al. Insulin resistance
is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diabetes and Vascular Disease
Research.2007; 4(2):130–5. PMID: 17654447
4. Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Solomon A. Independent role of conventional cardio-
vascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J Rheu-
matol.2007; 34(4):681–8. PMID: 17299845
5. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. Inflammation-associated insu-
lin resistance: Differential effects in rheumatoid arthritis and systemic lupus erythematosus define
potential mechanisms. Arthritis & Rheumatism.2008; 58(7):2105–12.
6. WaskoMC, Kay J, Hsia EC, RahmanMU. Diabetes mellitus and insulin resistance in patients with rheu-
matoid arthritis: Risk reduction in a chronic inflammatory disease. Arthritis care & research.2011; 63(4):
512–21.
7. Pamuk ON, Unlü E, Cakir N. Role of insulin resistance in increased frequency of atherosclerosis
detected by carotid ultrasonography in rheumatoid arthritis. J Rheumatol.2006; 33(12):2447–52. PMID:
17143979
8. Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z. The acute phase response does not fully predict
the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol.2002; 29(3):
462–6. PMID: 11908557
9. Sakthiswary R, Sazliyana SS, Shahrir MSM, Shahril NS, H H. Beyond the Joints in Rheumatoid Arthri-
tis: Effects of Adalimumab on Hematologic and Lipid Indices. Excli Journal.2012; 11:142–9.
TNF-Inhibitors and Insulin Sensitivity
PLOS ONE | DOI:10.1371/journal.pone.0128889 June 25, 2015 8 / 10
10. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of
insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science.1996;
271(5249):665–70. PMID: 8571133
11. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, et al. Anti-tumor necro-
sis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheuma-
toid arthritis patients with high insulin resistance. Arthritis Res Ther.2012; 14(3):R141. doi: 10.1186/
ar3874 PMID: 22691241
12. Turner R, Holman R, Matthews D, Hockaday T, Peto J. Insulin deficiency and insulin resistance interac-
tion in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin
and glucose concentrations. Metabolism.1979; 28(11):1086–96. PMID: 386029
13. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity
check index: a simple, accurate method for assessing insulin sensitivity in humans. The Journal of Clin-
ical Endocrinology & Metabolism.2000; 85(7):2402–10.
14. Otten J, Ahrén B, Olsson T. Surrogate measures of insulin sensitivity vs the hyperinsulinaemic–
euglycaemic clamp: a meta-analysis. Diabetologia.2014:1–8.
15. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the
size of a sample. BMCmedical research methodology.2005; 5(1):13.
16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality
of reports of randomized clinical trials: is blinding necessary? Controlled clinical trials.1996 Feb; 17(1):
1–12. PMID: 8721797
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials.1986; 7(3):177–88.
PMID: 3802833
18. Stavropoulos-Kalinoglou A, Metsios G, Panoulas V, Nightingale P, Koutedakis Y, Kitas G. Anti-tumour
necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients
with rheumatoid arthritis. Arthritis Res Ther.2012; 14(4):R160. doi: 10.1186/ar3900 PMID: 22765047
19. Ferraz-Amaro I, Arce-Franco M, Muñiz J, López-Fernández J, Hernández-Hernández V, Franco A,
et al. Systemic Blockade of TNF-α does not Improve Insulin Resistance in Humans. Hormone and Met-
abolic Research.2011 18.10.2011; 43(11):801–8. doi: 10.1055/s-0031-1287783 PMID: 22009376
20. Tam L- S, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids
levels in patients with rheumatoid arthritis. Clin Rheumatol.2007; 26(9):1495–8. PMID: 17237906
21. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen B. Insulin resistance in patients with rheumatoid
arthritis: effect of anti-TNFα therapy. Scand J Rheumatol.2007; 36(2):91–6. PMID: 17476613
22. Oguz F, Oguz A, Uzunlulu M. The effect of infliximab treatment on insulin resistance in patients with
rheumatoid arthritis. Acta Clin Belg.2007; 62(4):218–22. PMID: 17849692
23. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin
resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Annals of the rheumatic dis-
eases.2005; 64(5):765–6. PMID: 15458960
24. Seriolo B, Ferrone C, Cutolo M. Longterm anti-tumor necrosis factor-alpha treatment in patients with
refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Rheuma-
tol.2008; 35(2):355–7. PMID: 18260166
25. Oguz FM, Oguz A, Uzunlulu M. The effect of infliximab treatment on insulin resistance in patients with
rheumatoid arthritis. Acta Clin Belg.2007 Jul-Aug; 62(4):218–22. PMID: 17849692
26. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin
resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis.2005 May;
64(5):765–6. PMID: 15458960
27. Ferraz-Amaro I, Arce-Franco M, Muñiz J, López-Fernández J, Hernández-Hernández V, Franco A,
et al. Systemic Blockade of TNF-α does not Improve Insulin Resistance in Humans. HormMetab
Res.2011 18.10.2011; 43(11):801–8. doi: 10.1055/s-0031-1287783 PMID: 22009376
28. Seriolo B, Paolino S, Ferrone C, Cutolo M. Impact of long-term anti-TNF-alpha treatment on insulin
resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol.2008 Jan-Feb; 26(1):159–60.
PMID: 18328169
29. Gonzalez-Gay M, De Matias J, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J,
et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid
arthritis. Clin Exp Rheumatol.2006; 24(1):83–6. PMID: 16539824
30. Hällgren R, Berne C. Glucose intolerance in patients with chronic inflammatory diseases is normalized
by glucocorticoids. Acta medica Scandinavica.1983; 213(5):351–5. PMID: 6880857
31. Svenson KL, Pollare T, Lithell H, Hällgren R. Impaired glucose handling in active rheumatoid arthritis:
relationship to peripheral insulin resistance. Metabolism.1988; 37(2):125–30. PMID: 2893241
TNF-Inhibitors and Insulin Sensitivity
PLOS ONE | DOI:10.1371/journal.pone.0128889 June 25, 2015 9 / 10
32. Paolisso G, Valentini G, Giugliano D, Marrazzo G, Tirri R, Gallo M, et al. Evidence for peripheral
impaired glucose handling in patients with connective tissue diseases. Metabolism.1991; 40(9):902–7.
PMID: 1895954
33. Bili A, Sartorius JA, Kirchner HL, Morris SJ, Dancea S, Wasko MCM. Diabetes mellitus risk in rheuma-
toid arthritis: Reduced incidence with anti–tumor necrosis factor α therapy. Arthritis care & research.
2012; 64(2):215–21.
34. Cuchacovich R, Espinoza LR. Does TNF-alpha blockade play any role in cardiovascular risk among
rheumatoid arthritis (RA) patients? Clinical rheumatology.2009; 28(10):1217–20. doi: 10.1007/s10067-
009-1208-x PMID: 19517156
35. Pérez M, Ariza R, Asencio R, Camargo A, Garcia H, Vazquez MA, et al. Effect of Anti-TNF Therapy on
Resistance to Insulin in Patients with Rheumatoid Arthritis. Open Journal of Rheumatology and Autoim-
mune Diseases.2013; 3:167.
36. Rajappa M, Rathika S, Munisamy M, Chandrashekar L, Thappa D. Effect of treatment with methotrex-
ate and coal tar on adipokine levels and indices of insulin resistance and sensitivity in patients with pso-
riasis vulgaris. Journal of the European Academy of Dermatology and Venereology.2014; doi: 10.1111/
jdv.12451
37. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti–TNF-α antibody
(CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes.1996; 45(7):
881–5. PMID: 8666137
38. Gentile S, Guarino G, Bizzarro A, De Bellis A, Torella R. Infliximab does not interfere with insulin secre-
tion, insulin resistance and production of GAD and islet cell antibodies in patients with Crohn's disease.
Diabetes, Obesity and Metabolism.2002; 4(4):276–7. PMID: 12099977
39. Paquot N, Castillo MJ, Lefèbvre PJ, Scheen AJ. No Increased Insulin Sensitivity after a Single Intrave-
nous Administration of a Recombinant Human Tumor Necrosis Factor Receptor: Fc Fusion Protein in
Obese Insulin-Resistant Patients 1. The Journal of Clinical Endocrinology & Metabolism.2000; 85(3):
1316–9.
TNF-Inhibitors and Insulin Sensitivity
PLOS ONE | DOI:10.1371/journal.pone.0128889 June 25, 2015 10 / 10
